# A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

> **NCT06996782** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 152 (estimated)

## Conditions studied

- Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Rilvegostomig
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT06996782
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2029-02-23
- **Final completion:** 2029-02-23
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06996782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06996782, "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06996782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*